RxDoctor Payments Data

Randall Harada, MD

Interventional Cardiology · Vancouver, WANPI 1316972334

Payments from drug & device makers

$1,578in general payments, 2019–2025

Across 81 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$609
  • Abbott$288
  • Novo Nordisk$119
  • Pfizer$102
  • Johnson & Johnson$72
  • Cook Medical LLC$71
  • plus $317 from 9 others

What the payments were for

  • Food & beverage$1,56499%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,578 in reported general payments places this provider in the 25th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$439,678
Medicare patients
1,044
Services billed
3,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban294$379,045
XareltoRivaroxaban103$141,924
EntrestoSacubitril/Valsartan13$22,421
Repatha SureclickEvolocumab27$17,595
Dabigatran EtexilateDabigatran Etexilate Mesylate34$11,001
Metoprolol Succinate711$10,468
Atorvastatin Calcium359$5,670
Diltiazem 24hr Er (Cd)Diltiazem Hcl74$3,831
Losartan Potassium303$3,217
Amiodarone Hcl45$2,588
Digoxin96$2,547
PradaxaDabigatran Etexilate Mesylate12$2,497
Rosuvastatin Calcium113$2,062
Carvedilol183$1,950
Furosemide254$1,895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$379,045294 claims
Johnson & JohnsonXarelto$72$141,924103 claims
NovartisEntresto$71$22,42113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →